Anticancer agents : frontiers in cancer chemotherapy
Author(s)
Bibliographic Information
Anticancer agents : frontiers in cancer chemotherapy
（ACS symposium series, 796）
American Chemical Society, c2001
Available at / 8 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and indexes
Description and Table of Contents
Description
Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis
agents, antitumor vaccins, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.
Table of Contents
- Preface
- 1. Cancer Drug Discovery and Development: New Paradigms for a New Millennium
- 2. Evolutionary Biosynthesis of Anticancer Drugs
- 3. Some Recent Developments in the Synthesis and SAR of Novel Taxanes
- 4. New Generation Taxoids and Hybrids of Microtube-Stabilizing Anticancer Agents
- 5. Discodermolide and Taxol: A Synergistic Drug Combination in Human Carcinoma Cell Lines
- 6. Highly Efficient Semisynthesis of Biologically Active Epothilone Derivatives
- 7. Synthetic and Semisynthetic Analogs of Epothilones: Chemistry and Biological Activity
- 8. Synthesis and Biological Activity of Epothilones
- 9. Epothelones and Sarcodictyins: From Combinatorial to Designed Analogs
- 10. Synthesis and Structure-Activity Relationship Studies of Cryptophycins: A Novel Class of Potent Antimitotic Tumor Depsipeptides
- 11. Farnesyltransferase Inhibitors as Potential Anticancer Agents
- 12. Farnesyltransferase Inhibitors: From Squalene Synthase Inhibitors to the Clinical Agent BMS-214662
- 13. Inhibiting Farnesyl Protein Transferase with Sch-66336: Potentially a Selective Non-Cytotoxic herapy for Human Cancer
- 14. Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase
- 15. STI571: A New Treatment Modality for CML
- 16. The Discovery and Development of Second-Generation Matrix Metalloproteinase Inhibitors for the Treatment of Cancer
- 17. Prospects for Anti-Angiogenic Therapies Based upon VEGF Inhibition
- 18. Carbohydrate-Based Tumor Antigens as Anti-Tumor Vaccine Agents
- 19. Drugs to Enhance the Therapeutic Potency of Anti-Cancer Antibodies
- Author Index
by "Nielsen BookData"
